These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27109575)

  • 21. The orphan receptor GPR55 is a novel cannabinoid receptor.
    Ryberg E; Larsson N; Sjögren S; Hjorth S; Hermansson NO; Leonova J; Elebring T; Nilsson K; Drmota T; Greasley PJ
    Br J Pharmacol; 2007 Dec; 152(7):1092-101. PubMed ID: 17876302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GPR55: a new member of the cannabinoid receptor clan?
    Pertwee RG
    Br J Pharmacol; 2007 Dec; 152(7):984-6. PubMed ID: 17876300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding.
    Ramírez-Orozco RE; García-Ruiz R; Morales P; Villalón CM; Villafán-Bernal JR; Marichal-Cancino BA
    Curr Neuropharmacol; 2019; 17(10):947-960. PubMed ID: 31146657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.
    Pertwee RG
    Curr Med Chem; 2010; 17(14):1360-81. PubMed ID: 20166927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A potential role for GPR55 in gastrointestinal functions.
    Schicho R; Storr M
    Curr Opin Pharmacol; 2012 Dec; 12(6):653-8. PubMed ID: 23063456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (R,R')-4'-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility.
    Paul RK; Wnorowski A; Gonzalez-Mariscal I; Nayak SK; Pajak K; Moaddel R; Indig FE; Bernier M; Wainer IW
    Biochem Pharmacol; 2014 Feb; 87(4):547-61. PubMed ID: 24355564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the natural ligand of GPR55?
    Okuno T; Yokomizo T
    J Biochem; 2011 May; 149(5):495-7. PubMed ID: 21324983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Off-target cannabinoid effects mediated by GPR55.
    Henstridge CM
    Pharmacology; 2012; 89(3-4):179-87. PubMed ID: 22433274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor.
    Han S; Chen JJ; Chen JZ
    Mini Rev Med Chem; 2014 May; 14(5):426-43. PubMed ID: 24766386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products.
    An D; Peigneur S; Hendrickx LA; Tytgat J
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32709050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55.
    Henstridge CM; Balenga NA; Kargl J; Andradas C; Brown AJ; Irving A; Sanchez C; Waldhoer M
    Mol Endocrinol; 2011 Nov; 25(11):1835-48. PubMed ID: 21964594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology, signaling and physiological relevance of the G protein-coupled receptor 55.
    Balenga NA; Henstridge CM; Kargl J; Waldhoer M
    Adv Pharmacol; 2011; 62():251-77. PubMed ID: 21907912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities.
    Alqarni M; Myint KZ; Tong Q; Yang P; Bartlow P; Wang L; Feng R; Xie XQ
    Biochem Biophys Res Commun; 2014 Sep; 452(3):334-9. PubMed ID: 25148941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GPR55: Current knowledge and future perspectives of a purported "Type-3" cannabinoid receptor.
    Moriconi A; Cerbara I; Maccarrone M; Topai A
    Curr Med Chem; 2010; 17(14):1411-29. PubMed ID: 20166924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GPR55 ligands promote receptor coupling to multiple signalling pathways.
    Henstridge CM; Balenga NA; Schröder R; Kargl JK; Platzer W; Martini L; Arthur S; Penman J; Whistler JL; Kostenis E; Waldhoer M; Irving AJ
    Br J Pharmacol; 2010 Jun; 160(3):604-14. PubMed ID: 20136841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational Investigations on the Binding Mode of Ligands for the Cannabinoid-Activated G Protein-Coupled Receptor GPR18.
    Neumann A; Engel V; Mahardhika AB; Schoeder CT; Namasivayam V; Kieć-Kononowicz K; Müller CE
    Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32365486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.
    Floresta G; Apirakkan O; Rescifina A; Abbate V
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30200181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist.
    Brown AJ; Daniels DA; Kassim M; Brown S; Haslam CP; Terrell VR; Brown J; Nichols PL; Staton PC; Wise A; Dowell SJ
    J Pharmacol Exp Ther; 2011 Apr; 337(1):236-46. PubMed ID: 21233197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic synthesis of novel phosphoglycolipid analogues as potential agonists of GPR55.
    Abe J; Guy AT; Ding F; Greimel P; Hirabayashi Y; Kamiguchi H; Ito Y
    Org Biomol Chem; 2020 Nov; 18(41):8467-8473. PubMed ID: 33063071
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.